MINERVA NEUROSCIENCES, INC News Releases http://ir.minervaneurosciences.com/ MINERVA NEUROSCIENCES, INC News Releases en Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-announces-positive-top-line-results-0 Potential first-in-class, oral specific orexin- 2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar to or lower than the rate observed in the placebo group Improves depressive symptoms and sleep Mon, 13 May 2019 08:15:00 -0400 MINERVA NEUROSCIENCES, INC News Releases 9421 Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-reports-first-quarter-2019-financial WALTHAM, Mass. , May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter Mon, 06 May 2019 07:30:00 -0400 MINERVA NEUROSCIENCES, INC News Releases 9416 Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019 http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-report-first-quarter-2019-financial Management to host conference call WALTHAM, Mass. , April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release Mon, 29 Apr 2019 08:30:00 -0400 MINERVA NEUROSCIENCES, INC News Releases 9401 Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-presents-pre-clinical-data-suggesting Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM, Mass. , April 11, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. Thu, 11 Apr 2019 08:30:00 -0400 MINERVA NEUROSCIENCES, INC News Releases 9381 Minerva Neurosciences to Host Webcast Event on Schizophrenia http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-host-webcast-event-schizophrenia Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Mon, 18 Mar 2019 08:30:00 -0400 MINERVA NEUROSCIENCES, INC News Releases 9361 Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-reports-fiscal-2018-fourth-quarter-and Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia disorder Five key data readouts expected in 2019  Management to host conference call today at 8:30 a.m. Tue, 12 Mar 2019 07:30:00 -0400 MINERVA NEUROSCIENCES, INC News Releases 9356 Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019 http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-report-fiscal-2018-fourth-quarter-and-year Management to host conference call WALTHAM, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release Tue, 05 Mar 2019 08:00:00 -0500 MINERVA NEUROSCIENCES, INC News Releases 9341 Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-announces-new-patent-application-min-117 WALTHAM, Mass. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the filing of a U.S. Wed, 28 Nov 2018 08:00:00 -0500 MINERVA NEUROSCIENCES, INC News Releases 9236 Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018 http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-present-evercore-isi-healthconx-conference WALTHAM, Mass. , Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Evercore ISI Wed, 21 Nov 2018 08:30:00 -0500 MINERVA NEUROSCIENCES, INC News Releases 9226 Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-announces-results-dose-escalation-study Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial   All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc intervals   Tested Mon, 19 Nov 2018 08:00:00 -0500 MINERVA NEUROSCIENCES, INC News Releases 9221